National Longitudinal Cohort of Hematological Diseases (NICHE) - CART

Institute of Hematology & Blood Diseases Hospital, China

Status: Enrolling

Conditions: Hematological Malignancies

Study type: Observational

Funder types: Other

Identifiers

NCT06607289

NICHE-CART

Details and patient eligibility

About

This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies. A consortium of Phase IV clinical trials and real-world studies of Chimeric antigen receptors (CAR) T cell therapy will be established in China. Patient-level data from these studies will be collected to create a large real-world cohort. In addition, patients receiving CAR-T cell therapy for hematological malignancies identified from an existing hematology longitudinal cohort study, the National Longitudinal Cohort of Hematological Diseases (NICHE), will also be included in the study.

Enrollment: 1,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients with clinically diagnosed hematologic malignancies
• Patients treated with CAR-T cell therapy
• Signed the informed consent form